Politico reported.Offit’s comments come just days after Pfizer said it has begun testing its COVID-19 vaccine in a larger group of younger children.The company says it has also selected lower dosages of its shot compared to the volume given to individuals 12 and older.RELATED: Pfizer lowers COVID-19 vaccine dose for younger kids in next stage of trial"Although data shows that severe #COVID19 is rare in children, widespread vaccination is a critical tool to help stop transmission.
That’s why I’m excited we have begun dosing participants aged 5 to 11 in a global Phase 2/3 study of the Pfizer-BioNTech #COVID19 vaccine," Pfizer CEO Albert Bourla said in a statement on Twitter .Last month, an advisory panel for the U.S.